866-997-4948(US-Canada Toll Free)

Global Urological Cancer Therapeutics Drugs Market Insights, Forecast to 2025

Published By :

QYResearch

Published Date : Sep 2018

Category :

Pharmaceutical

No. of Pages : 124 Pages

This report studies the global market size of Urological Cancer Therapeutics Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Urological Cancer Therapeutics Drugs in these regions.
This research report categorizes the global Urological Cancer Therapeutics Drugs market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.

In 2017, the global Urological Cancer Therapeutics Drugs market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Urological Cancer Therapeutics Drugs market based on company, product type, application and key regions.

The various contributors involved in the value chain of Urological Cancer Therapeutics Drugs include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Urological Cancer Therapeutics Drugs include
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.

Market Size Split by Type
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)
Market Size Split by Application
Hospital
Medical Research Laboratory
Others

Market size split by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Urological Cancer Therapeutics Drugs market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.
To understand the structure of Urological Cancer Therapeutics Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Urological Cancer Therapeutics Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Urological Cancer Therapeutics Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Urological Cancer Therapeutics Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Urological Cancer Therapeutics Drugs are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025

This report includes the estimation of market size for value (million US$) and volume (Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Urological Cancer Therapeutics Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents

1 Study Coverage
1.1 Urological Cancer Therapeutics Drugs Product
1.2 Key Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Type
1.4.2 Xofigo (radium Ra 223 dichloride)
1.4.3 Jevtana (cabazitaxel)
1.4.4 Inlyta (axitinib)
1.4.5 Votrient (pazopanib hydrochloride)
1.4.6 Sutent (sunitinib malate)
1.4.7 Zytiga (abiraterone acetate)
1.4.8 Xtandi (enzalutamide)
1.4.9 Opdivo (nivolumab)
1.4.10 Provenge (sipuleucel-T)
1.5 Market by Application
1.5.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Medical Research Laboratory
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Urological Cancer Therapeutics Drugs Market Size
2.1.1 Global Urological Cancer Therapeutics Drugs Revenue 2016-2025
2.1.2 Global Urological Cancer Therapeutics Drugs Sales 2016-2025
2.2 Urological Cancer Therapeutics Drugs Growth Rate by Regions
2.2.1 Global Urological Cancer Therapeutics Drugs Sales by Regions
2.2.2 Global Urological Cancer Therapeutics Drugs Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Urological Cancer Therapeutics Drugs Sales by Manufacturers
3.1.1 Urological Cancer Therapeutics Drugs Sales by Manufacturers
3.1.2 Urological Cancer Therapeutics Drugs Sales Market Share by Manufacturers
3.1.3 Global Urological Cancer Therapeutics Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Urological Cancer Therapeutics Drugs Revenue by Manufacturers
3.2.1 Urological Cancer Therapeutics Drugs Revenue by Manufacturers (2016-2018)
3.2.2 Urological Cancer Therapeutics Drugs Revenue Share by Manufacturers (2016-2018)
3.3 Urological Cancer Therapeutics Drugs Price by Manufacturers
3.4 Urological Cancer Therapeutics Drugs Manufacturing Base Distribution, Product Types
3.4.1 Urological Cancer Therapeutics Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Urological Cancer Therapeutics Drugs Product Category
3.4.3 Date of International Manufacturers Enter into Urological Cancer Therapeutics Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type
4.1 Global Urological Cancer Therapeutics Drugs Sales by Type
4.2 Global Urological Cancer Therapeutics Drugs Revenue by Type
4.3 Urological Cancer Therapeutics Drugs Price by Type

5 Breakdown Data by Application
5.1 Overview
5.2 Global Urological Cancer Therapeutics Drugs Breakdown Data by Application

6 North America
6.1 North America Urological Cancer Therapeutics Drugs by Countries
6.1.1 North America Urological Cancer Therapeutics Drugs Sales by Countries
6.1.2 North America Urological Cancer Therapeutics Drugs Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Urological Cancer Therapeutics Drugs by Type
6.3 North America Urological Cancer Therapeutics Drugs by Application
6.4 North America Urological Cancer Therapeutics Drugs by Company

7 Europe
7.1 Europe Urological Cancer Therapeutics Drugs by Countries
7.1.1 Europe Urological Cancer Therapeutics Drugs Sales by Countries
7.1.2 Europe Urological Cancer Therapeutics Drugs Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Urological Cancer Therapeutics Drugs by Type
7.3 Europe Urological Cancer Therapeutics Drugs by Application
7.4 Europe Urological Cancer Therapeutics Drugs by Company

8 Asia Pacific
8.1 Asia Pacific Urological Cancer Therapeutics Drugs by Countries
8.1.1 Asia Pacific Urological Cancer Therapeutics Drugs Sales by Countries
8.1.2 Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Urological Cancer Therapeutics Drugs by Type
8.3 Asia Pacific Urological Cancer Therapeutics Drugs by Application
8.4 Asia Pacific Urological Cancer Therapeutics Drugs by Company

9 Central & South America
9.1 Central & South America Urological Cancer Therapeutics Drugs by Countries
9.1.1 Central & South America Urological Cancer Therapeutics Drugs Sales by Countries
9.1.2 Central & South America Urological Cancer Therapeutics Drugs Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Urological Cancer Therapeutics Drugs by Type
9.3 Central & South America Urological Cancer Therapeutics Drugs by Application
9.4 Central & South America Urological Cancer Therapeutics Drugs by Company

10 Middle East and Africa
10.1 Middle East and Africa Urological Cancer Therapeutics Drugs by Countries
10.1.1 Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Countries
10.1.2 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Urological Cancer Therapeutics Drugs by Type
10.3 Middle East and Africa Urological Cancer Therapeutics Drugs by Application
10.4 Middle East and Africa Urological Cancer Therapeutics Drugs by Company

11 Company Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Company Description
11.1.3 Sales, Revenue and Gross Margin of Urological Cancer Therapeutics Drugs
11.1.4 Urological Cancer Therapeutics Drugs Product Description
11.1.5 Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Company Description
11.2.3 Sales, Revenue and Gross Margin of Urological Cancer Therapeutics Drugs
11.2.4 Urological Cancer Therapeutics Drugs Product Description
11.2.5 Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Details
11.3.2 Company Description
11.3.3 Sales, Revenue and Gross Margin of Urological Cancer Therapeutics Drugs
11.3.4 Urological Cancer Therapeutics Drugs Product Description
11.3.5 Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Details
11.4.2 Company Description
11.4.3 Sales, Revenue and Gross Margin of Urological Cancer Therapeutics Drugs
11.4.4 Urological Cancer Therapeutics Drugs Product Description
11.4.5 Recent Development
11.5 Astellas
11.5.1 Astellas Company Details
11.5.2 Company Description
11.5.3 Sales, Revenue and Gross Margin of Urological Cancer Therapeutics Drugs
11.5.4 Urological Cancer Therapeutics Drugs Product Description
11.5.5 Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Details
11.6.2 Company Description
11.6.3 Sales, Revenue and Gross Margin of Urological Cancer Therapeutics Drugs
11.6.4 Urological Cancer Therapeutics Drugs Product Description
11.6.5 Recent Development
11.7 Abbott Laboratories
11.7.1 Abbott Laboratories Company Details
11.7.2 Company Description
11.7.3 Sales, Revenue and Gross Margin of Urological Cancer Therapeutics Drugs
11.7.4 Urological Cancer Therapeutics Drugs Product Description
11.7.5 Recent Development
11.8 Celgene Corporation
11.8.1 Celgene Corporation Company Details
11.8.2 Company Description
11.8.3 Sales, Revenue and Gross Margin of Urological Cancer Therapeutics Drugs
11.8.4 Urological Cancer Therapeutics Drugs Product Description
11.8.5 Recent Development
11.9 Dendreon Corporation
11.9.1 Dendreon Corporation Company Details
11.9.2 Company Description
11.9.3 Sales, Revenue and Gross Margin of Urological Cancer Therapeutics Drugs
11.9.4 Urological Cancer Therapeutics Drugs Product Description
11.9.5 Recent Development
11.10 Ferring Pharmaceuticals
11.10.1 Ferring Pharmaceuticals Company Details
11.10.2 Company Description
11.10.3 Sales, Revenue and Gross Margin of Urological Cancer Therapeutics Drugs
11.10.4 Urological Cancer Therapeutics Drugs Product Description
11.10.5 Recent Development
11.11 GlaxoSmithKline plc
11.12 Indevus Pharmaceuticals Inc
11.13 Ipsen
11.14 Roche Healthcare
11.15 Sanofi S.A.

12 Market Opportunities, Challenges, Risks and Influences Factors Analysis
12.1 Market Opportunities and Drivers
12.2 Market Challenges
12.3 Market Risks/Restraints
12.4 Key World Economic Indicators

13 Value Chain and Sales Channels Analysis
13.1 Value Chain Analysis
13.1.1 Typical Suppliers of Key Urological Cancer Therapeutics Drugs Raw Material
13.1.2 Urological Cancer Therapeutics Drugs Customers
13.2 Sales Channels Analysis
13.2.1 Sales Channels Analysis
13.2.2 Distributors

14 Research Findings and Conclusion

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
15.3 Disclaimer

List of Table

List of Tables and Figures

Figure Picture of Urological Cancer Therapeutics Drugs
Figure Global Urological Cancer Therapeutics Drugs Production (Units) and CAGR (%) Comparison by Types (Product Category) (2013-2025)
Figure Global Urological Cancer Therapeutics Drugs Production Market Share by Types (Product Category) in 2017
Figure Xofigo (radium Ra 223 dichloride) Product Picture
Table Major Manufacturers of Xofigo (radium Ra 223 dichloride)
Figure Jevtana (cabazitaxel) Product Picture
Table Major Manufacturers of Jevtana (cabazitaxel)
Figure Inlyta (axitinib) Product Picture
Table Major Manufacturers of Inlyta (axitinib)
Figure Votrient (pazopanib hydrochloride) Product Picture
Table Major Manufacturers of Votrient (pazopanib hydrochloride)
Figure Sutent (sunitinib malate) Product Picture
Table Major Manufacturers of Sutent (sunitinib malate)
Figure Zytiga (abiraterone acetate) Product Picture
Table Major Manufacturers of Zytiga (abiraterone acetate)
Figure Xtandi (enzalutamide) Product Picture
Table Major Manufacturers of Xtandi (enzalutamide)
Figure Opdivo (nivolumab) Product Picture
Table Major Manufacturers of Opdivo (nivolumab)
Figure Provenge (sipuleucel-T) Product Picture
Table Major Manufacturers of Provenge (sipuleucel-T)
Table Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Application 2018-2025 (Units)
Figure Hospital
Figure Medical Research Laboratory
Figure Others
Figure Urological Cancer Therapeutics Drugs Report Years Considered
Figure Global Urological Cancer Therapeutics Drugs Market Size 2016-2025 (Million US$)
Figure Global Urological Cancer Therapeutics Drugs Sales 2016-2025 (Units)
Table Global Urological Cancer Therapeutics Drugs Market Size by Regions 2016-2025 (Units) & (Million US$)
Table Global Urological Cancer Therapeutics Drugs Sales by Regions 2016-2025 (Units)
Table Global Urological Cancer Therapeutics Drugs Sales Market Share by Regions 2016-2025
Figure Global Urological Cancer Therapeutics Drugs Sales Market Share by Regions 2016-2025
Figure 2017 Global Urological Cancer Therapeutics Drugs Sales Market Share by Regions
Table Global Urological Cancer Therapeutics Drugs Revenue by Regions 2016-2025 (Million US$)
Table Global Urological Cancer Therapeutics Drugs Revenue Market Share by Regions 2016-2025
Figure Global Urological Cancer Therapeutics Drugs Revenue Market Share by Regions 2016-2025
Figure 2017 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Regions
Table Global Urological Cancer Therapeutics Drugs Sales by Manufacturers (2016-2018) (Units)
Table Global Urological Cancer Therapeutics Drugs Sales Share by Manufacturers (2016-2018)
Figure Global Urological Cancer Therapeutics Drugs Sales Share by Manufacturers in 2017
Table Urological Cancer Therapeutics Drugs Revenue by Manufacturers (2016-2018) (Million US$)
Table Urological Cancer Therapeutics Drugs Revenue Share by Manufacturers (2016-2018)
Figure Urological Cancer Therapeutics Drugs Value Share by Manufacturers in 2017
Table Global Urological Cancer Therapeutics Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Key Manufacturers Urological Cancer Therapeutics Drugs Price (2016-2018) (K USD/Unit)
Table Urological Cancer Therapeutics Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table Manufacturers Urological Cancer Therapeutics Drugs Product Category
Table Date of International Manufacturers Enter into Urological Cancer Therapeutics Drugs Market
Table Manufacturers Mergers & Acquisitions, Expansion Plans
Table Global Urological Cancer Therapeutics Drugs Sales by Type (2016-2025) (Units)
Table Global Urological Cancer Therapeutics Drugs Sales Share by Type (2016-2025)
Figure Global Urological Cancer Therapeutics Drugs Sales Market Share by Type (2016-2025)
Figure Global Urological Cancer Therapeutics Drugs Sales Market Share by Type in 2017
Table Global Urological Cancer Therapeutics Drugs Revenue by Type (2016-2025) (Million US$)
Table Global Urological Cancer Therapeutics Drugs Revenue Share by Type (2016-2025)
Figure Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2016-2025)
Figure Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type in 2017
Table Urological Cancer Therapeutics Drugs Price by Type 2013-2018 (K USD/Unit)
Table Global Urological Cancer Therapeutics Drugs Sales by Application (2016-2025) (Units)
Table Global Urological Cancer Therapeutics Drugs Sales Share by Application (2016-2025)
Figure Global Sales Urological Cancer Therapeutics Drugs Market Share by Application (2016-2025)
Figure Global Sales Urological Cancer Therapeutics Drugs Market Share by Application (2016-2025)
Figure North America Urological Cancer Therapeutics Drugs Sales Growth Rate 2016-2025 (Units)
Figure North America Urological Cancer Therapeutics Drugs Revenue Growth Rate 2016-2025 (Million US$)
Table North America Urological Cancer Therapeutics Drugs Sales by Countries (2016-2025) (Units)
Table North America Urological Cancer Therapeutics Drugs Sales Market Share by Countries (2016-2025)
Figure 2017 North America Urological Cancer Therapeutics Drugs Sales Market Share by Countries
Table North America Urological Cancer Therapeutics Drugs Revenue by Countries (2016-2025) (Million US$)
Table North America Urological Cancer Therapeutics Drugs Revenue Market Share by Countries (2016-2025)
Figure 2017 North America Urological Cancer Therapeutics Drugs Revenue Market Share by Countries
Figure United States Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure United States Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Canada Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure Canada Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Mexico Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure Mexico Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Table North America Urological Cancer Therapeutics Drugs Sales by Type (2016-2025) (Units)
Table North America Urological Cancer Therapeutics Drugs Sales Market Share by Type (2016-2025)
Figure 2017 North America Urological Cancer Therapeutics Drugs Market Share by Type
Table North America Urological Cancer Therapeutics Drugs Sales by Application (2016-2025) (Units)
Table North America Urological Cancer Therapeutics Drugs Sales Market Share by Application (2016-2025)
Figure 2017 North America Urological Cancer Therapeutics Drugs Market Share by Application
Table North America Urological Cancer Therapeutics Drugs Sales by Company (2016-2018) (Units)
Table North America Urological Cancer Therapeutics Drugs Sales Market Share by Company (2016-2018)
Figure North America Urological Cancer Therapeutics Drugs Sales Market Share by Company in 2017
Figure Europe Urological Cancer Therapeutics Drugs Sales Growth Rate 2016-2025 (Units)
Figure Europe Urological Cancer Therapeutics Drugs Revenue Growth Rate 2016-2025 (Million US$)
Table Europe Urological Cancer Therapeutics Drugs Sales by Countries (2016-2025) (Units)
Table Europe Urological Cancer Therapeutics Drugs Sales Market Share by Countries (2016-2025)
Figure 2017 Europe Urological Cancer Therapeutics Drugs Sales Market Share by Countries
Table Europe Urological Cancer Therapeutics Drugs Revenue by Countries (2016-2025) (Million US$)
Table Europe Urological Cancer Therapeutics Drugs Revenue Market Share by Countries (2016-2025)
Figure 2017 Europe Urological Cancer Therapeutics Drugs Revenue Market Share by Countries
Figure Germany Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure Germany Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Units)
Figure France Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure France Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Units)
Figure UK Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure UK Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Italy Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure Italy Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Russia Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure Russia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Table Europe Urological Cancer Therapeutics Drugs Sales by Type (2016-2025) (Units)
Table Europe Urological Cancer Therapeutics Drugs Sales Market Share by Type (2016-2025)
Figure 2017 Europe Urological Cancer Therapeutics Drugs Market Share by Type
Table Europe Urological Cancer Therapeutics Drugs Sales by Application (2016-2025) (Units)
Table Europe Urological Cancer Therapeutics Drugs Sales Market Share by Application (2016-2025)
Figure 2017 Europe Urological Cancer Therapeutics Drugs Market Share by Application
Table Europe Urological Cancer Therapeutics Drugs Sales by Company (2016-2018) (Units)
Table Europe Urological Cancer Therapeutics Drugs Sales Market Share by Company (2016-2018)
Figure Europe Urological Cancer Therapeutics Drugs Sales Market Share by Company in 2017
Figure Asia Pacific Urological Cancer Therapeutics Drugs Sales Growth Rate 2016-2025 (Units)
Figure Asia Pacific Urological Cancer Therapeutics Drugs Revenue Growth Rate 2016-2025 (Million US$)
Table Asia Pacific Urological Cancer Therapeutics Drugs Sales by Countries (2016-2025) (Units)
Table Asia Pacific Urological Cancer Therapeutics Drugs Sales Market Share by Countries (2016-2025)
Figure 2017 Asia Pacific Urological Cancer Therapeutics Drugs Sales Market Share by Countries
Table Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Countries (2016-2025) (Million US$)
Table Asia Pacific Urological Cancer Therapeutics Drugs Revenue Market Share by Countries (2016-2025)
Figure 2017 Asia Pacific Urological Cancer Therapeutics Drugs Revenue Market Share by Countries
Figure China Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure China Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Japan Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure Japan Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Korea Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure Korea Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure India Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure India Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Australia Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure Australia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Indonesia Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure Indonesia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Malaysia Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure Malaysia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Philippines Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure Philippines Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Thailand Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure Thailand Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Vietnam Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure Vietnam Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Singapore Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure Singapore Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Table Asia Pacific Urological Cancer Therapeutics Drugs Sales by Type (2016-2025) (Units)
Table Asia Pacific Urological Cancer Therapeutics Drugs Sales Market Share by Type (2016-2025)
Figure 2017 Asia Pacific Urological Cancer Therapeutics Drugs Market Share by Type
Table Asia Pacific Urological Cancer Therapeutics Drugs Sales by Application (2016-2025) (Units)
Table Asia Pacific Urological Cancer Therapeutics Drugs Sales Market Share by Application (2016-2025)
Figure 2017 Asia Pacific Urological Cancer Therapeutics Drugs Market Share by Application
Table Asia Pacific Urological Cancer Therapeutics Drugs Sales by Company (2016-2018) (Units)
Table Asia Pacific Urological Cancer Therapeutics Drugs Sales Market Share by Company (2016-2018)
Figure Asia Pacific Urological Cancer Therapeutics Drugs Sales Market Share by Company in 2017
Figure Central & South America Urological Cancer Therapeutics Drugs Sales Growth Rate 2016-2025 (Units)
Figure Central & South America Urological Cancer Therapeutics Drugs Revenue Growth Rate 2016-2025 (Million US$)
Table Central & South America Urological Cancer Therapeutics Drugs Sales by Countries (2016-2025) (Units)
Table Central & South America Urological Cancer Therapeutics Drugs Sales Market Share by Countries (2016-2025)
Figure 2017 Central & South America Urological Cancer Therapeutics Drugs Sales Market Share by Countries
Table Central & South America Urological Cancer Therapeutics Drugs Revenue by Countries (2016-2025) (Million US$)
Table Central & South America Urological Cancer Therapeutics Drugs Revenue Market Share by Countries (2016-2025)
Figure 2017 Central & South America Urological Cancer Therapeutics Drugs Revenue Market Share by Countries
Figure Brazil Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure Brazil Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Argentina Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure Argentina Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Table Central & South America Urological Cancer Therapeutics Drugs Sales by Type (2016-2025) (Units)
Table Central & South America Urological Cancer Therapeutics Drugs Sales Market Share by Type (2016-2025)
Figure 2017 Central & South America Urological Cancer Therapeutics Drugs Market Share by Type
Table Central & South America Urological Cancer Therapeutics Drugs Sales by Application (2016-2025) (Units)
Table Central & South America Urological Cancer Therapeutics Drugs Sales Market Share by Application (2016-2025)
Figure 2017 Central & South America Urological Cancer Therapeutics Drugs Market Share by Application
Table Central & South America Urological Cancer Therapeutics Drugs Sales by Company (2016-2018) (Units)
Table Central & South America Urological Cancer Therapeutics Drugs Sales Market Share by Company (2016-2018)
Figure Central & South America Urological Cancer Therapeutics Drugs Sales Market Share by Company in 2017
Figure Middle East and Africa Urological Cancer Therapeutics Drugs Sales Growth Rate 2016-2025 (Units)
Figure Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Growth Rate 2016-2025 (Million US$)
Table Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Countries (2016-2025) (Units)
Table Middle East and Africa Urological Cancer Therapeutics Drugs Sales Market Share by Countries (2016-2025)
Figure 2017 Middle East and Africa Urological Cancer Therapeutics Drugs Sales Market Share by Countries
Table Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Countries (2016-2025) (Million US$)
Table Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Market Share by Countries (2016-2025)
Figure 2017 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Market Share by Countries
Figure GCC Countries Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure GCC Countries Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Turkey Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure Turkey Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure Egypt Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure Egypt Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Figure South Africa Urological Cancer Therapeutics Drugs Sales Growth Rate (2016-2025) (Units)
Figure South Africa Urological Cancer Therapeutics Drugs Revenue Growth Rate (2016-2025) (Million US$)
Table Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Type (2016-2025) (Units)
Table Middle East and Africa Urological Cancer Therapeutics Drugs Sales Market Share by Type (2016-2025)
Figure 2017 Middle East and Africa Urological Cancer Therapeutics Drugs Market Share by Type
Table Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Application (2016-2025) (Units)
Table Middle East and Africa Urological Cancer Therapeutics Drugs Sales Market Share by Application (2016-2025)
Figure 2017 Middle East and Africa Urological Cancer Therapeutics Drugs Market Share by Application
Table Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Company (2016-2018) (Units)
Table Middle East and Africa Urological Cancer Therapeutics Drugs Sales Market Share by Company (2016-2018)
Figure Middle East and Africa Urological Cancer Therapeutics Drugs Sales Market Share by Company in 2017
Table Novartis Company Details
Table Novartis Urological Cancer Therapeutics Drugs Sales (Units), Revenue (Million US$), Price (K USD/Unit) and Gross Margin (2016-2018)
Table Novartis Recent Development
Table Pfizer Company Details
Table Pfizer Urological Cancer Therapeutics Drugs Sales (Units), Revenue (Million US$), Price (K USD/Unit) and Gross Margin (2016-2018)
Table Pfizer Recent Development
Table Johnson & Johnson Company Details
Table Johnson & Johnson Urological Cancer Therapeutics Drugs Sales (Units), Revenue (Million US$), Price (K USD/Unit) and Gross Margin (2016-2018)
Table Johnson & Johnson Recent Development
Table AstraZeneca Company Details
Table AstraZeneca Urological Cancer Therapeutics Drugs Sales (Units), Revenue (Million US$), Price (K USD/Unit) and Gross Margin (2016-2018)
Table AstraZeneca Recent Development
Table Astellas Company Details
Table Astellas Urological Cancer Therapeutics Drugs Sales (Units), Revenue (Million US$), Price (K USD/Unit) and Gross Margin (2016-2018)
Table Astellas Recent Development
Table Bristol-Myers Squibb Company Details
Table Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales (Units), Revenue (Million US$), Price (K USD/Unit) and Gross Margin (2016-2018)
Table Bristol-Myers Squibb Recent Development
Table Abbott Laboratories Company Details
Table Abbott Laboratories Urological Cancer Therapeutics Drugs Sales (Units), Revenue (Million US$), Price (K USD/Unit) and Gross Margin (2016-2018)
Table Abbott Laboratories Recent Development
Table Celgene Corporation Company Details
Table Celgene Corporation Urological Cancer Therapeutics Drugs Sales (Units), Revenue (Million US$), Price (K USD/Unit) and Gross Margin (2016-2018)
Table Celgene Corporation Recent Development
Table Dendreon Corporation Company Details
Table Dendreon Corporation Urological Cancer Therapeutics Drugs Sales (Units), Revenue (Million US$), Price (K USD/Unit) and Gross Margin (2016-2018)
Table Dendreon Corporation Recent Development
Table Ferring Pharmaceuticals Company Details
Table Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales (Units), Revenue (Million US$), Price (K USD/Unit) and Gross Margin (2016-2018)
Table Ferring Pharmaceuticals Recent Development
Table GlaxoSmithKline plc Company Details
Table Indevus Pharmaceuticals Inc Company Details
Table Ipsen Company Details
Table Roche Healthcare Company Details
Table Sanofi S.A. Company Details
Figure GDP by Regions / Largest Economies Pie Chart in 2016
Figure G20 GDP Long-Term Forecast Total, Million US dollars, 2060
Figure G20 Gross Domestic Product (GDP)Total, US Dollars/Capita, 2016
Figure Saving Rate Total, % of GDP, 2015
Table Urological Cancer Therapeutics Drugs Value Chain
Table Typical Suppliers of Key Urological Cancer Therapeutics Drugs Raw Material
Table Urological Cancer Therapeutics Drugs Customers List
Table Urological Cancer Therapeutics Drugs Sales Channels
Table Urological Cancer Therapeutics Drugs Distributors List
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *